Basal cell carcinoma is a slow-growing, locally invasive tumor. Locally it can be aggressive, destroy neighboring tissues, cause ulceration and invade deep into cartilage and bone. It is considered a chronic disease because many cases that develop their first basal cell carcinoma will subsequently develop at least one additional tumor, and a group of cases have more than one basal cell carcinoma at the time of diagnosis. HeberFERON is the combination of alpha2b and gamma IFNs with antiproliferative, antiangiogenic and immunomodulatory activity. It is a therapeutic modality used in the treatment of basal cell carcinoma and could have a remote effect on the rest of the tumors.